Atrial fibrillation in the Wolff-Parkinson-White syndrome: ECG recognition and treatment in the ED

American Journal of Emergency Medicine

Volumn 25, Issue 5, 2007, Pages 576-583

  Fengler, Brian T ^a   Brady, William J ^a   Plautz, Claire U ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IBUTILIDE; METOPROLOL; PROCAINAMIDE;

ADULT; ARTICLE; ATRIOVENTRICULAR CONDUCTION; CARDIOVERSION; CASE REPORT; CLINICAL FEATURE; DELTA RHYTHM; ELECTROCARDIOGRAM; EMERGENCY WARD; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEART RATE; HEART RHYTHM; HUMAN; MALE; PRIORITY JOURNAL; QRS COMPLEX; SYNCOPE; TREATMENT INDICATION; WOLFF PARKINSON WHITE SYNDROME;

ADULT; ATRIAL FIBRILLATION; ELECTROCARDIOGRAPHY; EMERGENCY SERVICE, HOSPITAL; HUMANS; MALE; WOLFF-PARKINSON-WHITE SYNDROME;

EID: 34249328098     PISSN: 07356757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajem.2006.10.017     Document Type: Article

References (26)

1. Willems J.L., Robles de Medina E.O., Bernard R., et al. Criteria for intraventricular conduction disturbances and pre-excitation. Am J Cardiol 5 (1985) 1261-1275
2. Becker A.E., Anderson R.H., Durrer D., and Wellens H.J.J. The anatomical substrates of Wolff-Parkinson-White syndrome. Circulation 57 (1978) 870
3. Sung R.J., and Tai D.Y. Electrophysiologic characteristics of accessory connections: an overview. In: Benditt D.G., and Benson D.W. (Eds). Cardiac pre-excitation syndromes: origins, evaluation, and treatment. 1st ed. (1986), Martinus Nijhoff Publishing, Boston 165-199
4. Al-Khatib S.M., and Pritchett E.L.C. Clinical features of Wolff-Parkinson-White syndrome. Am Heart J 138 (1999) 403-413
5. Ganz L.I., and Friedman P.L. Supraventricular tachycardia. N Engl J Med 332 (1995) 162-173
6. Wellens H.J.J., and Durrer D. Wolff-Parkinson-White syndrome and atrial fibrillation. Relation between refractory period of the accessory pathway and the ventricular rate during atrial fibrillation. Am J Cardiol 34 (1974) 777-782
7. Munger T.M., Packer D.L., Hammill S.C., et al. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953-1989. Circulation 87 (1993) 866-873
8. Klein G.J., et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 301 (1979) 1080-1085
9. Pieterson A.H., et al. Atrial fibrillation in Wolff-Parkinson-White syndrome. Am J Cardiol 70 (1992) 38A-43A
10. In: Cummins R.O., and Hazinski M.F. (Eds). Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care: an international consensus on science. Circulation 102 (Suppl) (2000) I1-I384 Suppl
11. AHA. Management of symptomatic bradycardia and tachycardia. Circulation 112 (2005) 67-77
12. Wellens H.J.J., Brugada P., Abdollah H., and Dassen W.R. A comparison of the electrophysiological effects of intravenous and oral amiodarone in the same patient. Circulation 69 (1984) 120-124
13. Singh B.N., et al. The historical development, cellular electrophysiology and pharmacology of amiodarone. Prog Cardiovasc Dis 31 (1989) 249-280
14. Talajic M., DeRoode M.R., and Nattel S. Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: evidence for clinically relevant activity of the metabolite. Circulation 75 (1987) 265-271
15. Scheinmann B.D., and Evans T. Acceleration of ventricular rate by amiodarone in atrial fibrillation associated with the Wolff-Parkinson-White syndrome. BMJ 285 (1982) 999-1000
16. Schutzenberger W., Leisch F., and Gmeiner R. Enhanced accessory pathway conduction following intravenous amiodarone in atrial fibrillation. Int J Cardiol 16 (1987) 93-95
17. Boriani G., et al. Ventricular fibrillation after intravenous in Wolff-Parkinson-White syndrome with atrial fibrillation. Am Heart J 131 (1996) 1214-1216
18. Murray K.T. Ibutilide. Circulation 97 (1998) 493-497
19. Gowda R.M., Khan I.A., et al. Use of ibutilide for cardioversion of recent-onset atrial fibrillation and flutter in the elderly. Am J Ther 11 (2004) 95-97
20. Ellenbogen K.A., Stambler B.S., Wood M.A., et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter. Am J Cardiol 28 1 (1996) 130-136
21. Stambler B.S., Wood M.A., and Ellenbogen K.A. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation. Circulation 96 (1997) 4298-4306
22. Volgman A.S., Carberry P.A., Stambler B., et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. JACC 31 6 (1998) 1414-1419
23. Viktorsdottir O., Henriksdottir A., and Arnar D.O. Ibutilide for treatment of atrial fibrillation in the emergency department. Emerg Med J 23 (2006) 133-134
24. Glatter K.A., et al. Electrophysiologic effects of ibutilide in patients with accessory pathways. Circulation (2001) 1933-1939
25. Sobel R.M., and Dhruva N.N. Termination of acute wide QRS complex atrial fibrillation with ibutilide. Am J Emerg Med 18 (2000) 462-464
26. Varriale P., Sedighi A., and Mirzaietehrane M. Ibutilide for termination of atrial fibrillation in the Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol 22 (1999) 1267-1269